Interesting result for BRCA patients from ASCO2018

[snoraste]

"Effect of germline DNA repair gene mutations on outcomes in men with metastatic castration-resistant

prostate cancer receiving first-line abiraterone and enzalutamide."

"Conclusions: Outcomes to first

line NHT appeared better in mCRPC patients harboring germline BRCA/ATM mutations (vs. no

mutations), but not for patients with other non-BRCA/ATM germline mutations. These results support the hypothesis that AR may promote DNA repair, and that inhibiting AR in the context of homologous recombination deficiency may lead to synthetic lethality."